Cambou J P, Ferrières J, Ruidavets J B, Ducimetière P
INSERM 326, ORSMIP, Projet MONICA, Chu Purpan.
Arch Mal Coeur Vaiss. 1996 Aug;89 Spec No 3:13-8.
Ischaemic heart disease is a perfect example of variability. The official mortality statistics in Europe show a gradient from 1 to 5. France is a zone at low risk even if deaths of undetermined causes are taken into account. This gradient is confirmed by the data from the Registries of the MONICA project. In France, the official mortality figures show a decrease of 28% in coronary mortality between 1985 and 1991 in men, throughout France. The differences in incidence of myocardial infarction between Lille and Toulouse in the MONICA project are not important but the differences in mortality are worrying. Between 1985 and 1991, the three registries show a 7% decrease in mortality (p < 0.001) and a 25% decrease in recurrences (p < 0.001) with an increase in primary infarcts of 8.3% (p < 0.05). There has been an increase in the prescription of betablockers, thrombolytics, ACE inhibitors and aspirin during the acute phase and at discharge form hospital. French cardiologists have followed the recommendations of the large scale clinical trials published during this period. The improved hospital mortality corresponds to the beneficial results reported in trials with aspirin, betablockers, ACE inhibitors and thrombolytics.
缺血性心脏病是变异性的一个典型例子。欧洲的官方死亡率统计显示出从1到5的梯度变化。即使将死因不明的死亡情况考虑在内,法国仍是低风险地区。莫尼卡项目登记处的数据证实了这种梯度变化。在法国,官方死亡率数据显示,1985年至1991年期间,法国男性的冠心病死亡率下降了28%。莫尼卡项目中里尔和图卢兹之间心肌梗死发病率的差异并不显著,但死亡率的差异令人担忧。1985年至1991年期间,三个登记处显示死亡率下降了7%(p<0.001),复发率下降了25%(p<0.001),而初次梗死增加了8.3%(p<0.05)。在急性期和出院时,β受体阻滞剂、溶栓剂、血管紧张素转换酶抑制剂和阿司匹林的处方量有所增加。法国心脏病专家遵循了这一时期发表的大规模临床试验的建议。住院死亡率的改善与阿司匹林、β受体阻滞剂、血管紧张素转换酶抑制剂和溶栓剂试验中报告的有益结果相符。